@article{oai:shiga-med.repo.nii.ac.jp:00004052,
 author = {福井, 里佳 and 寺田, 智祐 and 平, 大樹 and 國津, 侑貴 and 磯野, 哲一郎 and 田淵, 陽平 and 生野, 芳博 and 伊藤, 英樹 and 田中, 俊宏 and FUKUI, Rika and HIRA, Daiki and KUNITSU, Yuki and ISONO, Tetsuichiro and TABUCHI, Yohei and IKUNO, Yoshihiro and UESHIMA, Satoshi and ITOH, Hideki and TANAKA, Toshihiro and TERADA, Tomohiro},
 issue = {3},
 journal = {Journal of Clinical Biochemistry and Nutrition},
 month = {Nov},
 note = {pdf, In clinical practice, edoxaban is sometimes prescribed for off-label use based on the hypothesis that it is as safe and effective as warfarin. However, there is limited safety information on off-label use due to lack of clinical trial. We aimed to analyze the tolerability of off-label use of edoxaban and to identify patient characteristics associated with major bleeding as adverse effects. Patients under edoxaban treatment between January 2017 and December 2017 were enrolled in this retrospective cohort study. The incidence of major bleeding with off-label use compared with on-label use was analyzed using by log-rank test. Univariate and multivariate regression analysis were undertaken to detect independent variables with significant odds ratio that associated with major bleeding. After the exclusion criteria were applied, the patients were divided into two groups: off-label group (n = 30) and on-label group (n = 161). Incidence of major bleeding was found to be higher in the off-label group (13.3%) than in the on-label group (3.7%) (p<0.05). Multivariate adjustment showed that the off-label use or portal vein thrombosis and patients with history of major bleeding has significantly higher incidence of major bleeding. We demonstrated that off-label use of edoxaban may be a significant risk factor for major bleeding., Journal Article},
 pages = {311--316},
 title = {High incidence of major bleeding with off-label use of edoxaban},
 volume = {69},
 year = {2021}
}